FBLG FibroBiologics, Inc.
Debt Financing ·
FibroBiologics sold a $1,200,000 convertible debenture to Peak One Opportunity Fund, L.P. for $1,020,000, an original issue discount of 15%. The debenture matures October 8, 2027 and converts only after a default, at $0.78 per share.
Nasdaq staff says the bid price closed below $1.00 for 30 consecutive business days and that FibroBiologics gets no 180-day compliance period after a reverse stock split. The company intends to request a hearing.
Nasdaq staff plans to delist FibroBiologics after its stock did not regain the $1.00 minimum bid price by December 29, 2025. The company will ask for a hearing and has asked stockholders to approve a reverse split of 1 for 5 to 1 for 30.
FibroBiologics received a Nasdaq notice that its market value of listed securities is below the $35.0 million minimum. It has until February 2, 2026 to close at or above that level for ten business days, and the 8-K gives no current market value or remedy.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $7.4 million | $4.5 million |
| Net income (loss) | -$18.6 million | -$11.2 million |
| Cash from operations | -$16.4 million | -$11.9 million |
| Cash and equivalents | $4.9 million | $14.0 million |
Our latest story on this, dated Jul 24, 2026: "FibroBiologics gets Nasdaq delisting determination over $1.00 minimum bid price, plans appeal". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jul 24, 2026: "FibroBiologics gets Nasdaq delisting determination over $1.00 minimum bid price, plans appeal". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Oct 7, 2026: "FibroBiologics sells $1,200,000 convertible debenture to Peak One". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 8, 2025: "FibroBiologics gets Nasdaq notice for market value below $35.0 million". The story links the filing or release it is based on. Read the story.
FibroBiologics, Inc. trades under the ticker FBLG on NASDAQ.
FibroBiologics, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for FibroBiologics, Inc. is 1958777. Its filings are on SEC EDGAR.
6,658,193 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-07-31.
Our directory records FibroBiologics, Inc. under United States.
Our directory classifies FibroBiologics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for FibroBiologics, Inc. is US31573L2043.
aibio.space lists FibroBiologics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
FibroBiologics, Inc. reported a net loss of $18.6 million for the fiscal year ended Dec 31, 2025, and used $16.4 million of cash in operations, per its annual report to the SEC.
$7.4 million in the fiscal year ended Dec 31, 2025, per its annual report.
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.07,7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 7.01,8.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). Source
Reported a financing. SEC Form S-1. Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Reported a financing. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,2.03,3.02,7.01,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,9.01). Source
Filed a final prospectus for a securities offering. SEC Form 424B4. Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,2.03,3.02,5.02,7.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio